Literature DB >> 22377924

Cutaneous graft-versus-host disease--clinical considerations and management.

Peggy A Wu1, Edward W Cowen.   

Abstract

Graft-versus-host disease (GVHD) is the primary cause of non-relapse-related morbidity and mortality in patients who undergo hematopoietic stem cell transplantation. Dermatologic manifestations are common in both acute and chronic GVHD. In the acute setting, skin involvement often provides the first indication of GVHD and may progress to erythroderma and even skin necrolysis. In the chronic phase, skin involvement is extraordinarily polymorphic, potentially involves all layers of the skin and subcutaneous tissue, and presents in sclerotic and nonsclerotic forms. Management of cutaneous disease is challenging and ideally employs a multi-disciplinary approach and an understanding of the multiple medical issues facing patients with GVHD. The dermatologist plays a key role in caring for the patient with GVHD by providing an accurate diagnosis, determination of disease activity and response to treatment, and appropriate consideration of all available treatment modalities, including topical, systemic, and physical interventions (e.g. phototherapy, extracorporeal photopheresis). This chapter describes the cutaneous manifestations of acute and chronic GVHD and provides an evidence-based review of current treatment interventions for patients with GVHD skin disease.
Copyright © 2012 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22377924      PMCID: PMC7458413          DOI: 10.1159/000335270

Source DB:  PubMed          Journal:  Curr Probl Dermatol        ISSN: 1421-5721


  68 in total

1.  Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibility complex.

Authors:  K Le Blanc; L Tammik; B Sundberg; S E Haynesworth; O Ringdén
Journal:  Scand J Immunol       Date:  2003-01       Impact factor: 3.487

2.  Antibody responses to H-Y minor histocompatibility antigens correlate with chronic graft-versus-host disease and disease remission.

Authors:  David B Miklos; Haesook T Kim; Katherine H Miller; Luxuan Guo; Emmanuel Zorn; Stephanie J Lee; Ephraim P Hochberg; Catherine J Wu; Edwin P Alyea; Corey Cutler; Vincent Ho; Robert J Soiffer; Joseph H Antin; Jerome Ritz
Journal:  Blood       Date:  2004-12-21       Impact factor: 22.113

3.  Toxic serum levels of tacrolimus after topical administration in an infant with severe cutaneous graft-versus-host disease.

Authors:  S Prot-Labarthe; R Therrien; M A Champagne; M Duval; C Joubert
Journal:  Bone Marrow Transplant       Date:  2007-06-04       Impact factor: 5.483

4.  How I conduct a comprehensive chronic graft-versus-host disease assessment.

Authors:  Paul A Carpenter
Journal:  Blood       Date:  2011-06-30       Impact factor: 22.113

5.  Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo.

Authors:  Amelia Bartholomew; Cord Sturgeon; Mandy Siatskas; Karen Ferrer; Kevin McIntosh; Sheila Patil; Wayne Hardy; Steve Devine; David Ucker; Robert Deans; Annemarie Moseley; Ronald Hoffman
Journal:  Exp Hematol       Date:  2002-01       Impact factor: 3.084

6.  Consensus conference on clinical practice in chronic graft-versus-host disease (GVHD): first-line and topical treatment of chronic GVHD.

Authors:  Daniel Wolff; Armin Gerbitz; Francis Ayuk; Alexander Kiani; Gerhard C Hildebrandt; Georgia B Vogelsang; Sharon Elad; Anita Lawitschka; Gerard Socie; Steven Z Pavletic; Ernst Holler; Hildegard Greinix
Journal:  Biol Blood Marrow Transplant       Date:  2010-06-25       Impact factor: 5.742

Review 7.  Mesenchymal stem cells for treatment of acute and chronic graft-versus-host disease, tissue toxicity and hemorrhages.

Authors:  O Ringden; K Le Blanc
Journal:  Best Pract Res Clin Haematol       Date:  2011-02-25       Impact factor: 3.020

8.  Thalidomide for the treatment of chronic graft-versus-host disease.

Authors:  G B Vogelsang; E R Farmer; A D Hess; V Altamonte; W E Beschorner; D A Jabs; R L Corio; L S Levin; O M Colvin; J R Wingard
Journal:  N Engl J Med       Date:  1992-04-16       Impact factor: 91.245

9.  Sclerodermatous graft-vs-host disease: clinical and pathological study of 17 patients.

Authors:  Pablo F Peñas; María Jones-Caballero; Maximiliano Aragüés; Jesús Fernández-Herrera; Javier Fraga; Amaro García-Díez
Journal:  Arch Dermatol       Date:  2002-07

10.  Mesenchymal stem cell as salvage treatment for refractory chronic GVHD.

Authors:  J Y Weng; X Du; S X Geng; Y W Peng; Z Wang; Z S Lu; S J Wu; C W Luo; R Guo; W Ling; C X Deng; P J Liao; A P Xiang
Journal:  Bone Marrow Transplant       Date:  2010-09-06       Impact factor: 5.483

View more
  4 in total

Review 1.  Miniature Swine as a Clinically Relevant Model of Graft-Versus-Host Disease.

Authors:  Raimon Duran-Struuck; Christene A Huang; Katherine Orf; Roderick T Bronson; David H Sachs; Thomas R Spitzer
Journal:  Comp Med       Date:  2015-10       Impact factor: 0.982

2.  The immune reconstitution of the skin following sex-mismatched allogeneic haematopoietic stem cell transplant: a prospective case series utilizing fluorescence in situ hybridization and immunohistochemistry.

Authors:  C L Stewart; C M Cornejo; K A Wanat; I Sander; S Samimi; S Prouty; J Seykora; P Zhang; M Rosenbach; E J Kim; R G Micheletti
Journal:  Br J Dermatol       Date:  2018-01-08       Impact factor: 9.302

Review 3.  Drug induced exfoliative dermatitis: state of the art.

Authors:  Mona-Rita Yacoub; Alvise Berti; Corrado Campochiaro; Enrico Tombetti; Giuseppe Alvise Ramirez; Andrea Nico; Elisabetta Di Leo; Paola Fantini; Maria Grazia Sabbadini; Eustachio Nettis; Giselda Colombo
Journal:  Clin Mol Allergy       Date:  2016-08-22

4.  Atopic Dermatitis-like Graft-versus-host Disease and Lichen Planus-like Graft-versus-host Disease: Alterations in Skin Barrier Function and Related Molecules.

Authors:  Kun Li; Zhang-Lei Mu; Xue Chen; Guang-Dong Wen; Yan Zhao; Jian-Zhong Zhang
Journal:  Chin Med J (Engl)       Date:  2017-06-20       Impact factor: 2.628

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.